The estimated Net Worth of John Adam Zangerle is at least $8.92 millió dollars as of 15 June 2022. Mr Zangerle owns over 2,659 units of Steris Plc stock worth over $6,762,188 and over the last 9 years he sold STE stock worth over $1,219,724. In addition, he makes $940,375 as Sr. VP, Gen. Counsel és Sec. at Steris Plc.
Mr has made over 14 trades of the Steris Plc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,659 units of STE stock worth $545,919 on 15 June 2022.
The largest trade he's ever made was exercising 12,252 units of Steris Plc stock on 1 October 2020 worth over $655,727. On average, Mr trades about 1,272 units every 50 days since 2015. As of 15 June 2022 he still owns at least 27,936 units of Steris Plc stock.
You can see the complete history of Mr Zangerle stock trades at the bottom of the page.
John Adam Zangerle is the Sr. VP, Gen. Counsel, Sec. at Steris Plc.
As the Sr. VP, Gen. Counsel és Sec. of Steris Plc, the total compensation of Mr Zangerle at Steris Plc is $940,375. There are 8 executives at Steris Plc getting paid more, with Walter Rosebrough having the highest compensation of $6,458,640.
Mr Zangerle is 54, he's been the Sr. VP, Gen. Counsel és Sec. of Steris Plc since . There are 9 older and 13 younger executives at Steris Plc. The oldest executive at Steris Plc is David Lewis, 76, who is the Independent Director.
John's mailing address filed with the SEC is C/O 70 SIR JOHN ROGERSON'S QUAY, , DUBLIN, L2, 2.
Over the last 9 years, insiders at Steris Plc have traded over $157,726,045 worth of Steris Plc stock. The most active insiders traders include Richard Martin Steeves, Walter M Jr Rosebrough és John P Wareham. On average, Steris Plc executives and independent directors trade stock every 19 days with the average trade being worth of $3,374,074. The most recent stock trade was executed by Christopher S Holland on 8 August 2024, trading 473 units of STE stock currently worth $113,369.
steris is a leading provider of infection prevention and procedural surgical products and services, focused primarily on healthcare, pharmaceutical, research and medical device customers. our mission is to provide a healthier today and a safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. while the corporation was founded as innovative medical technologies in 1985 and renamed steris in 1987, our history dates back to 1894 with the founding of american sterilizer company, a long-time, global leading innovator of sterilization products. today, through a series of strategic acquisitions and continual innovation of new products, steris holds one of the broadest portfolios of products in the industry. it stands at the forefront of efforts to prevent infection and contamination in healthcare, pharmaceutical and medical device environments.
Steris Plc executives and other stock owners filed with the SEC include: